Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Successful use of cyclophosphamide as an add-on therapy for multiple myeloma patients with acquired resistance to bortezomib or lenalidomide.

Ito S, Oyake T, Murai K, Ishida Y.

Case Rep Hematol. 2013;2013:651902. doi: 10.1155/2013/651902. Epub 2013 Mar 28.

2.

Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.

Delforge M, Michiels A, Doyen C, Kentos A, Van Droogenbroeck J, Offner F, Bries G, Demuynck H, Vekemans MC, Meuleman N, Mineur PO, Ravoet C, Depryck B, Van de Velde A, Pierre P, Wu KL, Schots R.

Acta Clin Belg. 2011 Sep-Oct;66(5):371-5.

PMID:
22145272
3.

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.

Nijhof IS, Groen RW, Noort WA, van Kessel B, de Jong-Korlaar R, Bakker J, van Bueren JJ, Parren PW, Lokhorst HM, van de Donk NW, Martens AC, Mutis T.

Clin Cancer Res. 2015 Jun 15;21(12):2802-10. doi: 10.1158/1078-0432.CCR-14-1813. Epub 2014 Nov 14.

4.

The emerging role of novel therapies for the treatment of relapsed myeloma.

Richardson PG, Hideshima T, Mitsiades C, Anderson KC.

J Natl Compr Canc Netw. 2007 Feb;5(2):149-62. Review.

PMID:
17335684
5.

(Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.

Wang A, Duan Q, Liu X, Ding K, Han Y, Zhu W, Cai X, Wu J, Sun Z.

Ann Hematol. 2012 Nov;91(11):1779-84. doi: 10.1007/s00277-012-1520-4. Epub 2012 Jul 7.

PMID:
22773209
6.

A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.

Khan ML, Reeder CB, Kumar SK, Lacy MQ, Reece DE, Dispenzieri A, Gertz MA, Greipp P, Hayman S, Zeldenhurst S, Dingli D, Lust J, Russell S, Laumann KM, Mikhael JR, Leif Bergsagel P, Fonseca R, Vincent Rajkumar S, Keith Stewart A.

Br J Haematol. 2012 Feb;156(3):326-33. doi: 10.1111/j.1365-2141.2011.08949.x. Epub 2011 Nov 23.

PMID:
22107129
7.

Treatment of newly diagnosed myeloma.

Palumbo A, Rajkumar SV.

Leukemia. 2009 Mar;23(3):449-56. doi: 10.1038/leu.2008.325. Epub 2008 Nov 13. Review.

8.

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.

Kumar SK, Flinn I, Noga SJ, Hari P, Rifkin R, Callander N, Bhandari M, Wolf JL, Gasparetto C, Krishnan A, Grosman D, Glass J, Sahovic EA, Shi H, Webb IJ, Richardson PG, Rajkumar SV.

Leukemia. 2010 Jul;24(7):1350-6. doi: 10.1038/leu.2010.116. Epub 2010 May 27.

9.

LC-MS/MS method for simultaneous determination of thalidomide, lenalidomide, cyclophosphamide, bortezomib, dexamethasone and adriamycin in serum of multiple myeloma patients.

Shu C, Zeng T, Gao S, Xia T, Huang L, Zhang F, Chen W.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Aug 15;1028:111-119. doi: 10.1016/j.jchromb.2016.06.009. Epub 2016 Jun 7.

PMID:
27336703
10.

Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.

Chanan-Khan AA, San Miguel JF, Jagannath S, Ludwig H, Dimopoulos MA.

Clin Cancer Res. 2012 Apr 15;18(8):2145-63. doi: 10.1158/1078-0432.CCR-11-0498. Epub 2012 Feb 10. Review.

11.

Multiple myeloma maintenance therapy: a review of the pharmacologic treatment.

Shank BR, Brown VT, Schwartz RN.

J Oncol Pharm Pract. 2015 Feb;21(1):36-51. doi: 10.1177/1078155213514468. Epub 2014 Jan 6. Review.

PMID:
24395544
12.

Bortezomib and lenalidomide as front-line therapy for multiple myeloma.

Zou Y, Lin M, Sheng Z, Niu S.

Leuk Lymphoma. 2014 Sep;55(9):2024-31. doi: 10.3109/10428194.2013.847935. Epub 2013 Nov 6.

PMID:
24067138
13.

[Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy].

Takeda Y, Sakaida E, Nakaseko C.

Nihon Rinsho. 2015 Jan;73(1):130-6. Japanese.

PMID:
25626318
14.

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.

Laubach JP, Schlossman RL, Mitsiades CS, Anderson KC, Richardson PG.

Expert Rev Hematol. 2011 Feb;4(1):51-60. doi: 10.1586/ehm.10.83. Review.

PMID:
21322778
15.

Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.

Reece D, Imrie K, Stevens A, Smith CA; Hematology Disease Site Groupof Cancer Care Ontario’s Program in Evidence-based Care.

Curr Oncol. 2006 Oct;13(5):160-72.

16.

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.

Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina M, Schlossman RL, Mazumder A, Munshi NC, Ghobrial IM, Doss D, Warren DL, Lunde LE, McKenney M, Delaney C, Mitsiades CS, Hideshima T, Dalton W, Knight R, Esseltine DL, Anderson KC.

J Clin Oncol. 2009 Dec 1;27(34):5713-9. doi: 10.1200/JCO.2009.22.2679. Epub 2009 Sep 28.

17.

Pooled analysis of the reports of pomalidomide after failure of lenalidomide and (or) bortezomib for multiple myeloma.

Sheng Z, Liu G.

Hematol Oncol. 2016 Jun;34(2):102-7. doi: 10.1002/hon.2192. Epub 2015 Feb 3. Review.

PMID:
25643940
18.

Treatment of relapsed/refractory multiple myeloma.

Kastritis E, Palumbo A, Dimopoulos MA.

Semin Hematol. 2009 Apr;46(2):143-57. doi: 10.1053/j.seminhematol.2009.01.004. Review.

PMID:
19389498
19.

Lenalidomide in multiple myeloma.

Richardson PG, Mitsiades C, Hideshima T, Anderson KC.

Expert Rev Anticancer Ther. 2006 Aug;6(8):1165-73. Review.

PMID:
16925483
20.

The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.

Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Redman KC, McKenney M, Warren D, Noonan K, Lunde L, Doss D, Colson K, Hideshima T, Mitsiades C, Munshi NC, Anderson KC.

Eur J Haematol. 2012 May;88(5):446-9. doi: 10.1111/j.1600-0609.2012.01765.x. Epub 2012 Mar 7.

PMID:
22300348

Supplemental Content

Support Center